Miami Valley Hospital South Leads Global BELLA Trial Testing Relacorilant for Platinum-Resistant Ovarian Cancer
Key Insights
Miami Valley Hospital South (search) becomes the first of 23 international sites to open enrollment for the BELLA study, testing relacorilant in combination with chemotherapy for advanced ovarian cancer.
The trial targets patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer (search) that has progressed after platinum-based chemotherapy (search) treatment.
Relacorilant is designed to block hormone signals (search) that cause cancer resistance to chemotherapy, potentially making cancer cells more responsive to treatment.
Premier Health (search)'s Miami Valley Hospital South (search) has achieved a significant milestone by becoming the first site globally to open enrollment for the BELLA clinical trial, an international study testing an investigational drug combination for patients with advanced ovarian and related cancers. The trial represents a new approach to overcoming treatment resistance in platinum-refractory gynecologic malignancies.
Novel Hormone-Blocking Approach
The BELLA study investigates whether relacorilant, an investigational medication designed to block certain hormone signals (search), can enhance the effectiveness of chemotherapy and targeted therapy in cancer patients. The drug's mechanism focuses on making cancer cells more responsive to treatment by interrupting hormone pathways that may contribute to chemotherapy resistance.
"The goal is giving access locally to the highest level of cancer care," said Dr. Michael Guy, principal investigator for the study at Miami Valley Hospital South (search). Guy emphasized that being selected as the first enrollment site worldwide reflects Premier Health (search)'s clinical capabilities and commitment to expanding treatment options for cancer patients.
Patient Population and Treatment Protocol
The study targets adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (search) that has returned or progressed following platinum-based chemotherapy (search). This patient population represents a significant unmet medical need, as treatment options become limited after platinum resistance develops.
Qualifying patients receive a combination of oral and IV medications administered during monthly treatment cycles. All study visits are conducted at the Miami Valley Hospital South (search) campus located at 2400 Miami Valley Drive in Centerville.
Global Trial Network
The BELLA study represents a substantial international research effort, with ten sites in the United States participating alongside hospitals in Belgium, France, Germany, Italy, Korea, Poland, and Spain. According to hospital officials, the study will ultimately expand to include more than 50 sites worldwide.
Miami Valley Hospital South (search) has already enrolled its first patient in the study, marking the beginning of what could be a significant advancement in treating platinum-resistant gynecologic cancers. The hospital's selection as the lead enrollment site underscores the institution's research infrastructure and clinical expertise.
Research Portfolio Context
Premier Health (search)'s involvement in the BELLA trial is part of a broader commitment to cancer research, with the health system currently participating in 70 cancer-related clinical trials according to its website. This extensive research portfolio positions the organization as a significant contributor to oncology drug development and patient access to experimental therapies.
Patients interested in learning about eligibility for the BELLA study or other cancer trials at Premier Health (search) can contact the Office of Clinical Trials at 937-915-2515 or email clinicaltrials@premierhealth.com.